- Home
- PCYO vs ABEO Comparison
PCYO vs ABEO Comparison
Compare PCYO & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCYO | ABEO |
|---|---|---|
| Founded | 1976 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.7M | 281.0M |
| IPO Year | N/A | 1980 |
Fundamental Metrics
Financial Performance| Metric | PCYO | ABEO |
|---|---|---|
| Price | $11.77 | $5.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $18.20 |
| AVG Volume (30 Days) | 43.4K | ★ 1.4M |
| Earning Date | 01-07-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.50 | N/A |
| EPS | 0.54 | ★ 1.29 |
| Revenue | ★ $26,087,000.00 | $400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,590.36 |
| P/E Ratio | $21.67 | ★ $3.82 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.65 | $3.93 |
| 52 Week High | $13.21 | $7.54 |
Technical Indicators
Market Signals| Indicator | PCYO | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 55.27 | 51.39 |
| Support Level | $11.39 | $4.80 |
| Resistance Level | $11.80 | $5.61 |
| Average True Range (ATR) | 0.33 | 0.25 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 48.17 | 45.58 |
Price Performance
Historical ComparisonAbout PCYO Pure Cycle Corporation
Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in two business segments namely Water and wastewater resource development and Land development. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.